Literature DB >> 15905743

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.

Kristel M Crommentuyn, Alwin D Huitema, Kees Brinkman, Marchina E van der Ende, Frank de Wolf, Jos H Beijnen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15905743

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  4 in total

1.  Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.

Authors:  Betty J Dong; Yu Zheng; Michael D Hughes; Adam Frymoyer; Davide Verotta; Patricia Lizak; Frederick Sawe; Judith S Currier; Shahin Lockman; Francesca T Aweeka
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

Review 2.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.

Authors:  Tim R Cressey; Sawitree Nangola; Yardpiroon Tawon; Mookda Pattarawarapan; Marc Lallemant; Chatchai Tayapiwatana
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

4.  A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.

Authors:  Nils von Hentig; Amina Carlebach; Peter Gute; Gaby Knecht; Stefan Klauke; Maren Rohrbacher; Hartmut Stocker; Michael Kurowski; Sebastian Harder; Schlomo Staszewski; Annette Haberl
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.